ProVisc: Main Uses and Benefits

ProVisc is a highly purified viscoelastic preparation utilized as a surgical aid in ophthalmic procedures involving the anterior segment of the eye. Its primary use is during the process of cataract extraction and intraocular lens (IOL) implantation.

---

Quick Facts

• Therapeutic Domain: Ophthalmic surgery.
• Key Use 1: Employed during cataract removal procedures.
• Key Use 2: Facilitates the implantation of intraocular lenses.
• Core Benefit: Serves to temporarily maintain space in the anterior chamber during surgery.

---

The preparation functions to maintain a deep anterior chamber during the procedure, which may reduce the risk of trauma to the corneal endothelium and surrounding ocular tissues. The viscoelastic properties of the product assist in creating and preserving space within the eye's anterior segment, a key requirement for the successful performance of cataract and IOL implantation surgery.

Regulatory References

1. FDA medical device regulation overview

Who can and cannot use ProVisc?

Eligibility for ProVisc is strictly defined by regulatory documents, focusing on patient status and specific ocular conditions.

Absolute Non-Eligibility

The primary absolute prohibition is a contraindication for patients with a known hypersensitivity or allergy to Sodium Hyaluronate or any other component in the ProVisc formulation.

Age and Life Stage Eligibility

Use is established in adults and older adults as the target population for anterior segment surgeries. However, use in pediatric patients is not established. Furthermore, safety has not been established for use in pregnant or lactating women.

Conditional Use and Restrictions

Patients with pre-existing conditions like glaucoma or ocular hypertension may use ProVisc, but their use is restricted and requires special consideration. Regulatory authorities mandate close monitoring of intraocular pressure immediately post-operatively due to the risk of transient elevation. Systemic conditions such as renal or hepatic impairment are generally not listed as restrictions for this locally confined intraocular device.

Interactions with other medicines and products

The official regulatory profile for ProVisc (Sodium Hyaluronate Ophthalmic Viscosurgical Device) is defined by its transient, non-systemic use during intraocular surgical procedures. This classification governs its interaction structure, which is characterized by the absence of systemic drug interactions and the presence of a specific chemical incompatibility restriction.

Systemic Drug-Drug Interactions

Regulatory documentation confirms no known clinically significant systemic interactions with other medicinal products. The compound is administered directly into the eye’s anterior segment and is not absorbed into the general circulation in a manner that would affect the metabolism or clearance of co-administered systemic drugs. Consequently, the labeling does not include warnings for interactions related to pharmacokinetic pathways, such as CYP450 enzyme inhibition or induction, or drug transporter mechanisms. Furthermore, no interactions with food, alcohol, or herbal products are documented.

Chemical Incompatibility Restriction

The only documented interaction restriction is based on the chemical incompatibility of the viscoelastic solution with certain external substances. The labeling prohibits contact between ProVisc and solutions containing cationic agents, including quaternary ammonium salts and chlorhexidine. This restriction is mandatory because contact with these substances causes the Sodium Hyaluronate polymer to chemically precipitate, physically altering the integrity and effectiveness of the solution as a surgical aid. This is classified as a strict procedural constraint within the local surgical environment.

How ProVisc Works

ProVisc's action is defined by its role as a sterile viscoelastic solution, utilizing the physicochemical properties of high molecular weight Sodium Hyaluronate rather than biochemical signaling to exert its effects. The mechanism is purely rheological.

Mechanism of Spatial Integrity and Support

The material's high viscosity and cohesion allow it to physically occupy and provide mechanical support for the anterior chamber space. This action establishes a deep and controlled working volume by displacing the natural aqueous humor. The consequence of this physical displacement is the establishment of temporary spatial integrity among the internal ocular structures, which mechanically dampens movement and collapse during manipulation.

Mechanical Buffering and Surface Coating

ProVisc acts as a mechanical buffer by adhering to and coating sensitive cell surfaces, notably the Corneal Endothelium. This unique coating mechanism dissipates the mechanical energy and shear stress generated by surgical instrumentation and fluid flow. This action reduces physical stressors on the endothelium, supporting its cellular integrity and viability against trauma.

Viscous Modulation of Fluid Dynamics

The extreme thickness of the solution causes a temporary, localized modulation of intraocular fluid dynamics, effectively slowing or halting the natural flow of aqueous humor. The high viscosity creates a quiescent fluid environment, reducing fluid turbulence and rapid pressure fluctuations within the segment. This same viscous property, however, requires thorough aspiration to mitigate the risk of transient mechanical impedance of the eye's natural outflow pathway.

How ProVisc is Used: Administration Guidelines

ProVisc is an Ophthalmic Viscosurgical Device (OVD) based on Sodium Hyaluronate. The general principle of its use is to serve as a temporary surgical aid rather than a conventional drug administered over time, focusing entirely on administration during surgery.

---

Administration Scope

Feature	Instruction
Route of administration	Intraocular instillation directly into the anterior segment of the eye.
Dosing schedule	Volume-dependent dosing; the volume administered (typically 0.5 mL to 1.0 mL) is sufficient to maintain surgical space. The full contents of the single-use syringe are the maximum quantity intended per eye for one procedure.
Preparation requirements	The product is supplied ready-to-use and must be allowed to reach room temperature (18 °C to 25 °C) prior to instillation.
Age-group rules	No dose adjustments are specified based on age or systemic organ function, as use is local.

---

Procedural Structure and Constraints

ProVisc is a single-application product, meaning the frequency is limited to once per operative eye during the procedure itself. Administration must be performed by a qualified ophthalmic surgeon under strict aseptic technique in a sterile operating environment. The product is designated for temporary intraoperative use, with its functional duration limited to the phase requiring space maintenance.

Any unused portion of the solution must be immediately discarded after the surgery, and the syringe is not to be re-sterilized or reused. Crucially, the viscoelastic material is required to be actively aspirated or irrigated from the eye at the time the procedure is concluded.

Research evidence / Overview of studies for ProVisc

Evidence for Use as a Surgical Aid in Cataract and IOL Implantation

This section summarizes the structure of Randomized Controlled Trials (RCTs) and Systematic Reviews that investigated ProVisc's use as a viscoelastic agent during cataract extraction and Intraocular Lens (IOL) implantation. The focus will be on the study designs that examined the assessment of sensitive eye tissues and the maintenance of the surgical space.

The research examined how this product and similar viscoelastic agents performed in the specific context of ophthalmic surgery, where maintaining a controlled working area and assessing the corneal lining are key. Studies explored factors related to patient-reported outcomes describing perceived discomfort and the temporary physiological imbalance often monitored immediately after the procedure. Researchers primarily monitored the health of the corneal endothelial cells by counting them before and after surgery. Studies also monitored the patterns of temporary Intraocular Pressure (IOP) changes that can occur in the first few hours or days following the procedure.

Studies Comparing ProVisc to Other Viscoelastic Agents

This part covers the comparative study landscape, describing the research that assessed ProVisc against other officially approved ophthalmic viscosurgical devices (OVDs). It will explain what outcomes, such as postoperative pressure changes and tissue integrity markers, were measured in the research comparing these agents.

Many of the studies conducted were comparative trials, which means they focused on evaluating the differences or similarities between ProVisc and other viscoelastic products currently used in surgery. Findings describe observed patterns related to corneal cell loss and temporary pressure increases for the different viscoelastic products studied. The data show patterns related to how well the surgical space was maintained, which was often assessed by the surgeon. These comparative trials contribute to the broader evidence landscape for devices used in ophthalmic surgery.

Remaining Research Gaps and Uncertainties

This final section consolidates the known limitations and areas where data remain incomplete, according to scientific literature. This includes summarizing where research may lack extensive data on complex surgical scenarios, where results were noted to be heterogeneous, or where data relies on a short observation period.

Research findings highlight what is known and what is still uncertain about the use of this product outside of the specific controlled conditions studied in the original clinical trials. Comparative evidence remains limited regarding the differential performance of viscoelastic agents, as many trials were structured to explore performance non-inferiority. Furthermore, long-term effects are not fully established, as follow-up durations were limited to the short-to-intermediate term, and sample sizes were modest in some of the component trials.

Key Studies & References

1. Sodium hyaluronate in the treatment of dry eye after cataract surgery: a meta-analysis

Common questions about ProVisc (FAQ)

---

Q: How quickly can a person expect to feel a change after starting ProVisc?

ProVisc is classified as a temporary surgical aid and its function is immediate upon injection into the eye during the procedure. According to official product information, it is used only intraoperatively (during surgery) to maintain space and protect sensitive tissues. Its mechanical function concludes when the surgeon actively removes the product at the end of the procedure.

---

Q: How long does ProVisc stay in the body?

Regulatory documents indicate that the material is required to be actively aspirated or irrigated from the eye by the surgeon at the conclusion of the surgery. Any small amount of the material (Sodium Hyaluronate) that remains is naturally eliminated from the eye’s anterior chamber over a period of days.

---

Q: Is ProVisc safe to take long-term?

ProVisc is officially indicated for a single-use application as a temporary surgical aid during ophthalmic procedures, not for long-term use. Research evidence indicates that long-term effects beyond the short-to-intermediate term have not been fully established in the literature.

---

Q: Is it normal to feel tired when first starting ProVisc?

The official safety profile is restricted to localized ocular events, meaning effects only within the eye. Regulatory documentation confirms the product is for local intraocular use and is not absorbed into the general circulation in a way that affects the body systemically. Therefore, systemic effects like tiredness or fatigue are not documented in the safety profile.

---

Q: Can ProVisc affect my ability to drive or operate machinery?

Official precautions note the potential for transient increases in intraocular pressure and other temporary visual disturbances, such as corneal swelling, immediately following the procedure. These effects may temporarily affect eyesight, and regulatory documents caution about temporary visual impairment following the procedure.

---

Q: Can ProVisc be used during pregnancy?

Official documents state that the safety has not been established for use in pregnant or lactating women. Official documents consistently state that the safety profile for use in these life stages is not established.

---

Q: Can I crush or split the ProVisc tablet/capsule?

ProVisc is supplied as a sterile viscoelastic solution in a single-use syringe for administration by a surgeon, directly into the eye during a procedure. It is not available in tablet or capsule form and is never intended to be taken orally.

---

Q: Are there any signs that I should stop taking ProVisc immediately?

Regulatory warnings mention the potential for severe reactions, including signs of allergic or hypersensitivity and acute inflammatory responses, such as iritis. In the event of any severe or unexpected reaction, contact with the operating surgeon or medical professional is indicated.

---

Q: Why do some patient groups warn about combining ProVisc with supplements?

The official labeling confirms that the product has no known systemic interactions with food, alcohol, or herbal products/supplements because it is used only locally in the eye. The only documented incompatibility is a chemical one with certain cleaning agents used in the surgical field.

---

Q: Is ProVisc available over the counter?

ProVisc is classified as a specialized Ophthalmic Viscosurgical Device (OVD). It is intended only for professional use by a qualified ophthalmic surgeon in a sterile operating environment and is not available for purchase over the counter.

---

Q: Does ProVisc cause problems with sleeping?

The official safety profile is restricted to localized ocular events (reactions within the eye). Regulatory documents do not record any systemic side effects that could affect sleep, such as drowsiness or insomnia.

---

Q: Are there any common foods that interact with ProVisc?

Regulatory documentation confirms there are no known interactions with food. This is because the product is used transiently during the surgical procedure and is not absorbed into the general circulation.

---

Q: Is ProVisc safe for children?

Official documents state that use in pediatric patients (children) is not established. The product is commonly studied and used in adults for anterior segment surgeries.

---

Q: Do I need a special monitoring test while taking ProVisc?

The official precaution is that intraocular pressure (IOP) should be carefully monitored after the procedure. The precaution states that this monitoring is mandated due to the reporting of transient pressure increases following the surgery.

---

Q: What if I vomit shortly after taking ProVisc?

ProVisc is a sterile solution administered only via intraocular instillation (placed inside the eye) by a surgeon during the procedure. It is not intended to be taken orally, so issues related to oral ingestion are not applicable.

---

Q: Is a metallic taste in the mouth a common side effect of ProVisc?

The safety profile is limited to localized ocular events within the eye. Systemic effects like a metallic taste are not documented, as the product is not absorbed into the general circulation.

---

Q: Are there any known side effects on mood or mental health from ProVisc?

The official safety profile focuses on local eye-related reactions and does not document any known systemic side effects related to mood or mental health, consistent with its localized use.

---

Q: Does ProVisc change how other medications are absorbed?

Regulatory documents confirm no known clinically significant systemic interactions with other medications. The product is not absorbed into the general circulation in a way that would affect the metabolism or absorption of systemic drugs.

---

Q: Are there any specific supplements that should be avoided with ProVisc?

Due to the product's non-systemic use, the labeling confirms no known systemic interactions with food, alcohol, or herbal products/supplements. The only interaction restrictions relate to chemicals encountered directly during the surgical procedure.

---

Q: Is it possible to become dependent on ProVisc?

ProVisc is classified as a temporary surgical aid with a mechanical function. It is not a pharmacologically active substance that is absorbed systemically or used repeatedly over time; therefore, physical dependence is not a relevant concern.

---

Q: Can ProVisc make my skin more sensitive to the sun?

The official safety profile is restricted to localized ocular events within the eye. Systemic effects like photosensitivity (sun sensitivity) are not documented in regulatory information.

---

Q: Does taking ProVisc require special changes to my diet?

Regulatory documentation confirms there are no known interactions with food due to the product’s non-systemic, transient use. Therefore, no special changes to your diet are required.

---

Q: Is there a blood test that shows if ProVisc is working?

ProVisc's function is mechanical (space maintenance) and is observed directly by the surgeon during the procedure itself. There is no blood test required or relevant to assess its function as a surgical aid.

---

Q: How long after stopping ProVisc can I safely take an interacting medication?

Regulatory documentation confirms no known clinically significant systemic interactions with other medications. As the product is removed at the time of surgery and is not absorbed systemically, no special waiting period is necessary.

How to Store and Dispose of ProVisc: Official Regulatory Information

The official requirements for storing and disposing of ProVisc are based on maintaining the product's sterility and stability for professional use.

---

Storage Requirements

Condition	Requirement
Temperature	Store in a refrigerator between 2 C to 8 C (36 F to 46 F).
Protection	Protect from freezing and exposure to light.
Handling	Allow refrigerated product to warm to room temperature prior to use.
Packaging	Use only if the original sterile packaging is unopened and undamaged.

Disposal Requirements

ProVisc is for single use only. All unused contents, the used syringe, and any contaminated materials must be discarded immediately after the procedure. Disposal must be performed in accordance with applicable laws and regulations for biohazardous materials and clinical waste. The device should not be reused under any circumstances.